<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338649</url>
  </required_header>
  <id_info>
    <org_study_id>Light Therapy in PD</org_study_id>
    <nct_id>NCT01338649</nct_id>
  </id_info>
  <brief_title>Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence</brief_title>
  <official_title>Effects of Bright Light Treatment on Daytime Sleepiness and Nocturnal Sleep in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Parkinson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives are to determine the efficacy, safety and tolerability of bright light
      treatment in Parkinson's Disease (PD) patients with daytime sleepiness. Thirty PD patients
      will be enrolled and equally randomized to bright light or dim-red light treatment. Objective
      (actigraphy) and subjective (sleep logs/scales) sleep measures will be collected through the
      baseline and intervention phases of the study. The primary outcome measure will be the change
      in the Epworth Sleepiness Scale (ESS) comparing the bright light treatment with dim-red light
      treatment. Secondary outcome measures will include the Multiple Sleep Latency Test (MSLT),
      global Pittsburgh Sleep Quality Index (PSQI) score, Parkinson's Disease Sleep Scale (PDSS)
      score, and actigraphy measures. A variety of exploratory analyses will examine the effects of
      bright light treatment on fatigue, depression, quality of life, cognition, and motor
      disability.

      Hypothesis: Bright light exposure will diminish daytime sleepiness and improve night-time
      sleep in PD patients with daytime sleepiness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Epworth Sleepiness Scale (ESS) Scores Comparing the Bright Light Exposure With Dim-red Light Exposure.</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>ESS score range is 0-24; lower ESS scores indicate less daytime sleepiness; higher ESS scores indicate more severe sleepiness ESS will be taken and compared at screening and week 4 visits between the bright light exposure and dim-red light exposure groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Global PSQI Score and PDSS Score Will be Compared.</measure>
    <time_frame>6 weeks</time_frame>
    <description>The global PSQI and PDSS scores will be taken and compared at screening, week 4 and week 6 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraphy Measures Including Total Sleep Time, Sleep Efficiency, Sleep Fragmentation Index, Frequency of Naps, and Mean Activity Level (a Measurement of Daytime Function) Will be Collected.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Actigraphy measures including total sleep time, sleep efficiency, sleep fragmentation index, frequency of naps, and mean activity levelwill be completed for 3 - 2 week intervals by the subjects at home. Actigraphy measures will be collected at weeks 2, 4 and 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSLT and Polysomnograph (PSG) Testing Will be Compared.</measure>
    <time_frame>4 weeks</time_frame>
    <description>MSLT and PSG testing will take place prior to light intervention at screening 2 and post light intervention at week 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Sleep Disorder; Excessive Somnolence</condition>
  <arm_group>
    <arm_group_label>Bright White</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exposure to bright white light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dim red light</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exposure to dim red light treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bright Light Treatment (Sun Ray Sunbox SB-558)</intervention_name>
    <description>Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.</description>
    <arm_group_label>Bright White</arm_group_label>
    <other_name>Sun Ray Sunbox SB-558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dim red light (Sun Ray Sunbox SB-558)</intervention_name>
    <description>Dim red light box administered during two 1 hour periods during the day using</description>
    <arm_group_label>Dim red light</arm_group_label>
    <other_name>Sun Ray Sunbox SB-558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of idiopathic PD as defined by the United Kingdom Parkinson's Disease
             Society Brain Bank Criteria

          2. Hoehn and Yahr stage of 2 to 4 in the &quot;on&quot; state

          3. Excessive daytime sleepiness as defined by the Epworth Sleepiness Scale (ESS) score of
             greater than or equal to 12 points

          4. Stable PD medication regimen for at least 4 weeks prior to study screening

          5. Willing and able to give written informed consent

        Exclusion Criteria:

          1. Atypical parkinsonian syndromes

          2. Significant sleep disordered breathing (defined as an apnea-hypopnea index &gt;15
             events/hr of sleep on screening PSG)

          3. Significant periodic limb movement disorder (defined as a PLM arousal index&gt;10
             events/hr of sleep on screening PSG) and REM sleep behavior disorder (based on the
             presence of both clinical symptomatology as well as intermittent loss of REM atonia on
             screening PSG)

          4. Cognitive impairment indicated by the mini-mental status examination (MMSE) score of
             less than 24

          5. Presence of depression defined as the Beck Depression Inventory (BDI) score &gt;14

          6. Untreated hallucinations or psychosis (drug-induced or spontaneous)

          7. Use of hypno-sedative drugs for sleep or stimulants during the daytime

          8. Use of antidepressants unless the patient has been on a stable dose for at least three
             months

          9. Visual abnormalities that may interfere with light therapy, such as significant
             cataracts, narrow angle glaucoma or blindness

         10. Travel through 2 time zones within 90 days prior to study screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandar Videnovic, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 1988 Dec;11(6):512-9.</citation>
    <PMID>3233589</PMID>
  </reference>
  <reference>
    <citation>Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998 Nov;13(6):895-9.</citation>
    <PMID>9827612</PMID>
  </reference>
  <reference>
    <citation>Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):584-9.</citation>
    <PMID>11032608</PMID>
  </reference>
  <reference>
    <citation>Scaravilli T, Gasparoli E, Rinaldi F, Polesello G, Bracco F. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci. 2003 Oct;24(3):209-10.</citation>
    <PMID>14598091</PMID>
  </reference>
  <reference>
    <citation>Meindorfner C, Körner Y, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP. Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005 Jul;20(7):832-42.</citation>
    <PMID>15726539</PMID>
  </reference>
  <reference>
    <citation>Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord. 1990;5(4):280-5.</citation>
    <PMID>2259351</PMID>
  </reference>
  <reference>
    <citation>Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol. 1998 May;245 Suppl 1:S15-8. Review.</citation>
    <PMID>9617717</PMID>
  </reference>
  <reference>
    <citation>Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord. 2003 Jun;18(6):659-67.</citation>
    <PMID>12784269</PMID>
  </reference>
  <reference>
    <citation>Rye DB, Bliwise DL, Dihenia B, Gurecki P. FAST TRACK: daytime sleepiness in Parkinson's disease. J Sleep Res. 2000 Mar;9(1):63-9.</citation>
    <PMID>10733691</PMID>
  </reference>
  <reference>
    <citation>Lockley SW, Skene DJ, Arendt J, Tabandeh H, Bird AC, Defrance R. Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab. 1997 Nov;82(11):3763-70.</citation>
    <PMID>9360538</PMID>
  </reference>
  <reference>
    <citation>Myers BL, Badia P. Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Neurosci Biobehav Rev. 1995 Winter;19(4):553-71. Review. Erratum in: Neurosci Biobehav Rev 1996 Summer;20(2):I-IV.</citation>
    <PMID>8684716</PMID>
  </reference>
  <reference>
    <citation>Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res. 1972 Jul 13;42(1):201-6.</citation>
    <PMID>5047187</PMID>
  </reference>
  <reference>
    <citation>Dijk DJ, Lockley SW. Integration of human sleep-wake regulation and circadian rhythmicity. J Appl Physiol (1985). 2002 Feb;92(2):852-62. Review.</citation>
    <PMID>11796701</PMID>
  </reference>
  <reference>
    <citation>Moore-Ede MC, Czeisler CA, Richardson GS. Circadian timekeeping in health and disease. Part 2. Clinical implications of circadian rhythmicity. N Engl J Med. 1983 Sep 1;309(9):530-6. Review.</citation>
    <PMID>6348546</PMID>
  </reference>
  <reference>
    <citation>Czeisler CA, Allan JS, Strogatz SH, Ronda JM, Sánchez R, Ríos CD, Freitag WO, Richardson GS, Kronauer RE. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science. 1986 Aug 8;233(4764):667-71.</citation>
    <PMID>3726555</PMID>
  </reference>
  <reference>
    <citation>Wever RA, Polásek J, Wildgruber CM. Bright light affects human circadian rhythms. Pflugers Arch. 1983 Jan;396(1):85-7.</citation>
    <PMID>6835810</PMID>
  </reference>
  <reference>
    <citation>Van Someren EJ, Riemersma RF, Swaab DF. Functional plasticity of the circadian timing system in old age: light exposure. Prog Brain Res. 2002;138:205-31. Review.</citation>
    <PMID>12432772</PMID>
  </reference>
  <reference>
    <citation>Shochat T, Martin J, Marler M, Ancoli-Israel S. Illumination levels in nursing home patients: effects on sleep and activity rhythms. J Sleep Res. 2000 Dec;9(4):373-9.</citation>
    <PMID>11386204</PMID>
  </reference>
  <reference>
    <citation>Mishima K, Okawa M, Shimizu T, Hishikawa Y. Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab. 2001 Jan;86(1):129-34.</citation>
    <PMID>11231989</PMID>
  </reference>
  <reference>
    <citation>Klerman EB, Duffy JF, Dijk DJ, Czeisler CA. Circadian phase resetting in older people by ocular bright light exposure. J Investig Med. 2001 Jan;49(1):30-40. doi: 10.2310/6650.2001.34088.</citation>
    <PMID>11217145</PMID>
  </reference>
  <reference>
    <citation>Kobayashi R, Kohsaka M, Fukuda N, Sakakibara S, Honma H, Koyama T. Effects of morning bright light on sleep in healthy elderly women. Psychiatry Clin Neurosci. 1999 Apr;53(2):237-8.</citation>
    <PMID>10459698</PMID>
  </reference>
  <reference>
    <citation>Kaida K, Takahashi M, Haratani T, Otsuka Y, Fukasawa K, Nakata A. Indoor exposure to natural bright light prevents afternoon sleepiness. Sleep. 2006 Apr;29(4):462-9.</citation>
    <PMID>16676779</PMID>
  </reference>
  <reference>
    <citation>Phipps-Nelson J, Redman JR, Dijk DJ, Rajaratnam SM. Daytime exposure to bright light, as compared to dim light, decreases sleepiness and improves psychomotor vigilance performance. Sleep. 2003 Sep;26(6):695-700.</citation>
    <PMID>14572122</PMID>
  </reference>
  <reference>
    <citation>Schindler SD, Graf A, Fischer P, Tölk A, Kasper S. Paranoid delusions and hallucinations and bright light therapy in Alzheimer's disease. Int J Geriatr Psychiatry. 2002 Nov;17(11):1071-2.</citation>
    <PMID>12404657</PMID>
  </reference>
  <reference>
    <citation>Fetveit A, Bjorvatn B. Bright-light treatment reduces actigraphic-measured daytime sleep in nursing home patients with dementia: a pilot study. Am J Geriatr Psychiatry. 2005 May;13(5):420-3.</citation>
    <PMID>15879592</PMID>
  </reference>
  <reference>
    <citation>Dowling GA, Hubbard EM, Mastick J, Luxenberg JS, Burr RL, Van Someren EJ. Effect of morning bright light treatment for rest-activity disruption in institutionalized patients with severe Alzheimer's disease. Int Psychogeriatr. 2005 Jun;17(2):221-36.</citation>
    <PMID>16050432</PMID>
  </reference>
  <reference>
    <citation>Ancoli-Israel S, Martin JL, Gehrman P, Shochat T, Corey-Bloom J, Marler M, Nolan S, Levi L. Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):194-203.</citation>
    <PMID>12611749</PMID>
  </reference>
  <reference>
    <citation>Ancoli-Israel S, Gehrman P, Martin JL, Shochat T, Marler M, Corey-Bloom J, Levi L. Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behav Sleep Med. 2003;1(1):22-36.</citation>
    <PMID>15600135</PMID>
  </reference>
  <reference>
    <citation>Dowling GA, Mastick J, Hubbard EM, Luxenberg JS, Burr RL. Effect of timed bright light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2005 Aug;20(8):738-43.</citation>
    <PMID>16035127</PMID>
  </reference>
  <reference>
    <citation>Artemenko AR, Levin IaI. [The phototherapy of parkinsonism patients]. Zh Nevrol Psikhiatr Im S S Korsakova. 1996;96(3):63-6. Russian.</citation>
    <PMID>8992840</PMID>
  </reference>
  <reference>
    <citation>Reid KJ, Burgess HJ. Circadian rhythm sleep disorders. Prim Care. 2005 Jun;32(2):449-73. Review.</citation>
    <PMID>15935195</PMID>
  </reference>
  <reference>
    <citation>Kogan AO, Guilford PM. Side effects of short-term 10,000-lux light therapy. Am J Psychiatry. 1998 Feb;155(2):293-4.</citation>
    <PMID>9464216</PMID>
  </reference>
  <reference>
    <citation>Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson's disease. Age Ageing. 2006 May;35(3):220-8. Review.</citation>
    <PMID>16638765</PMID>
  </reference>
  <reference>
    <citation>Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003 Mar;18(3):287-93.</citation>
    <PMID>12621632</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>September 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Aleksandar Videnovic</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Daytime somnolence</keyword>
  <keyword>Sleepiness</keyword>
  <keyword>Light therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bright White</title>
          <description>Bright white light treatment group.
Bright Light Treatment (Sun Ray Sunbox SB-558): Bright white light box using light intensity of 10,000 lux, administered during two 1 hour periods during the day.</description>
        </group>
        <group group_id="P2">
          <title>Dim Red Light</title>
          <description>Dim red light control group.
Dim red light (Sun Ray Sunbox SB-558): Dim red light box administered during two 1 hour periods during the day using</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bright White</title>
          <description>Bright white light treatment group.
Bright Light Treatment (Sun Ray Sunbox SB-558): Bright white light box using light intensity of 10,000 lux, administered during two 1 hour periods during the day.</description>
        </group>
        <group group_id="B2">
          <title>Dim Red Light</title>
          <description>Dim red light control group.
Dim red light (Sun Ray Sunbox SB-558): Dim red light box administered during two 1 hour periods during the day using</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="6.9"/>
                    <measurement group_id="B2" value="59.3" spread="11.3"/>
                    <measurement group_id="B3" value="63.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>number of participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Epworth Sleepiness Scale (ESS) Scores Comparing the Bright Light Exposure With Dim-red Light Exposure.</title>
        <description>ESS score range is 0-24; lower ESS scores indicate less daytime sleepiness; higher ESS scores indicate more severe sleepiness ESS will be taken and compared at screening and week 4 visits between the bright light exposure and dim-red light exposure groups.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bright White</title>
            <description>Bright white light treatment group.
Bright Light Treatment (Sun Ray Sunbox SB-558): Bright white light box using light intensity of 10,000 lux, administered during two 1 hour periods during the day.</description>
          </group>
          <group group_id="O2">
            <title>Dim Red Light</title>
            <description>Dim red light control group.
Dim red light (Sun Ray Sunbox SB-558): Dim red light box administered during two 1 hour periods during the day using</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Epworth Sleepiness Scale (ESS) Scores Comparing the Bright Light Exposure With Dim-red Light Exposure.</title>
          <description>ESS score range is 0-24; lower ESS scores indicate less daytime sleepiness; higher ESS scores indicate more severe sleepiness ESS will be taken and compared at screening and week 4 visits between the bright light exposure and dim-red light exposure groups.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" spread="2.54"/>
                    <measurement group_id="O2" value="1.77" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0211</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t-test on two groups of differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Global PSQI Score and PDSS Score Will be Compared.</title>
        <description>The global PSQI and PDSS scores will be taken and compared at screening, week 4 and week 6 visits.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actigraphy Measures Including Total Sleep Time, Sleep Efficiency, Sleep Fragmentation Index, Frequency of Naps, and Mean Activity Level (a Measurement of Daytime Function) Will be Collected.</title>
        <description>Actigraphy measures including total sleep time, sleep efficiency, sleep fragmentation index, frequency of naps, and mean activity levelwill be completed for 3 - 2 week intervals by the subjects at home. Actigraphy measures will be collected at weeks 2, 4 and 6.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MSLT and Polysomnograph (PSG) Testing Will be Compared.</title>
        <description>MSLT and PSG testing will take place prior to light intervention at screening 2 and post light intervention at week 4.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bright White</title>
          <description>Bright white light treatment group.
Bright Light Treatment (Sun Ray Sunbox SB-558): Bright white light box using light intensity of 10,000 lux, administered during two 1 hour periods during the day.</description>
        </group>
        <group group_id="E2">
          <title>Dim Red Light</title>
          <description>Dim red light control group.
Dim red light (Sun Ray Sunbox SB-558): Dim red light box administered during two 1 hour periods during the day using</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>itchy eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>sleepiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aleksandar Videnovic</name_or_title>
      <organization>Northwestern University</organization>
      <phone>3126234033</phone>
      <email>aleksvidenovic@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

